Last reviewed · How we verify
IMM-101
IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity.
IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity. Used for Advanced melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).
At a glance
| Generic name | IMM-101 |
|---|---|
| Also known as | Heat-killed whole cell M. obuense, Heat killed whole cell M. obuense National Collection of Type Cultures (NCTC) 13365, Heat killed whole cell Mycobacterium obuense (M. obuense), Heat killed M. obuense (NCTC 13365) |
| Sponsor | Immodulon Therapeutics Ltd |
| Drug class | Cancer immunotherapy vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IMM-101 is a heat-killed whole cell vaccine derived from Mycobacterium obuense that acts as an immunological adjuvant. It is designed to prime and activate innate and adaptive immune responses, enhancing the body's ability to recognize and attack cancer cells. The vaccine is being developed as a combination therapy to potentiate checkpoint inhibitors and other immunotherapies.
Approved indications
- Advanced melanoma (in combination with checkpoint inhibitors)
- Non-small cell lung cancer (in combination with checkpoint inhibitors)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
- Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (PHASE3)
- A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer (PHASE2)
- Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin (PHASE2)
- Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (PHASE1, PHASE2)
- A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer (PHASE2)
- A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (PHASE2)
- A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 (PHASE1, PHASE2)
- A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMM-101 CI brief — competitive landscape report
- IMM-101 updates RSS · CI watch RSS
- Immodulon Therapeutics Ltd portfolio CI